Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Nov;8(11):643-57.
doi: 10.1038/nrneph.2012.214. Epub 2012 Oct 2.

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

Julien Zuber  1 , Fadi Fakhouri, Lubka T Roumenina, Chantal Loirat, Véronique Frémeaux-Bacchi; French Study Group for aHUS/C3G
Collaborators, Affiliations
Review

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

Julien Zuber et al. Nat Rev Nephrol. 2012 Nov.

Abstract

In the past decade, a large body of evidence has accumulated in support of the critical role of dysregulation of the alternative complement pathway in atypical haemolytic uraemic syndrome (aHUS) and C3 glomerulopathies. These findings have paved the way for innovative therapeutic strategies based on complement blockade, and eculizumab, a monoclonal antibody targeting the human complement component 5, is now widely used to treat aHUS. In this article, we review 28 case reports and preliminary data from 37 patients enrolled in prospective trials of eculizumab treatment for episodes of aHUS involving either native or transplanted kidneys. Eculizumab may be considered as an optimal first-line therapy when the diagnosis of aHUS is unequivocal and this treatment has the potential to rescue renal function when administered early after onset of the disease. However, a number of important issues require further study, including the appropriate duration of treatment according to an individual's genetic background and medical history, the optimal strategy to prevent post-transplantation recurrence of aHUS and a cost-efficacy analysis. Data regarding the efficacy of eculizumab in the control of C3 glomerulopathies are more limited and less clear, but several observations suggest that eculizumab may act on the most inflammatory forms of this disorder.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hematology Am Soc Hematol Educ Program. 2008;:116-23 - PubMed
    1. J Am Soc Nephrol. 2010 Dec;21(12):2180-7 - PubMed
    1. Nephrol Dial Transplant. 2008 Jun;23(6):2088-90 - PubMed
    1. N Engl J Med. 2009 Oct 22;361(17):1676-87 - PubMed
    1. Transplant Proc. 2010 Dec;42(10):4353-5 - PubMed

MeSH terms

Substances

LinkOut - more resources

-